<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565070</url>
  </required_header>
  <id_info>
    <org_study_id>BIOFREEZE OSTEOARTHRITIS</org_study_id>
    <secondary_id>HYGIENIC CORPORATION</secondary_id>
    <nct_id>NCT01565070</nct_id>
  </id_info>
  <brief_title>Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic</brief_title>
  <official_title>Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biofreeze® is a topical ointment that has menthol and alcamphor. Its analgesic effect lies in
      the stimulation of A and C fibers by cold and nociceptive stimulation, respectively, which is
      produced by menthol, apparently through the newly discovered receptor TRPM8 (Transient
      Receptor Potential melastatin-8) The aim of this study is to investigate if BIOFREEZE ®
      treatment (Performance Health Inc., Export, PA) improves symptoms associated with moderate
      knee osteoarthritis, which would decrease the immobility and isolation in older adults.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The local authorities did not authorize the use of biofreeze in Chile.
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC score</measure>
    <time_frame>60 days</time_frame>
    <description>WOMAC score corresponds to Western Ontario and McMaster Universities Index of Osteoarthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured using SF 36</measure>
    <time_frame>60 days</time_frame>
    <description>SF 36 correponds to a health related quality of life score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Biofreeze</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of placebo ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biofreeze</intervention_name>
    <description>Use of Biofreeze ointment</description>
    <arm_group_label>Biofreeze</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Use of placebo ointment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate osteoarthritis of the knee

          -  Age 60 to 80 years

          -  Ambulatory

        Exclusion Criteria:

          -  Other conditions that affect mobility

          -  Severe chronic diseases such as cardiac or renal failure

          -  Cancer

          -  Presence of gout

          -  Cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Bunout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INTA University of Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nutrition and Food Technology</name>
      <address>
        <city>Santiago</city>
        <state>Met</state>
        <zip>7830489</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Zhang J, Enix D, Snyder B, Giggey K, Tepe R. Effects of Biofreeze and chiropractic adjustments on acute low back pain: a pilot study. J Chiropr Med. 2008 Jun;7(2):59-65. doi: 10.1016/j.jcme.2008.02.004.</citation>
    <PMID>19674721</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Daniel Bunout</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Pain</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

